New state generics complaint is tougher on execs

Forty four states have sued 20 of the largest generic drugmakers – particularly targeting Teva Pharmaceuticals – alleging price manipulation, restraint of trade and other antitrust violations.

Get unlimited access to all Global Competition Review content